Fresenius Kabi Contract Manufacturing

CuraTeQ Biologics, based in Hyderabad, 60, is an EU GMP certified biopharmaceutical company specializing in the research, development, and manufacture of high-quality biosimilars and biologics. With a strategic focus on oncology and immunology, CuraTeQ has built a strong pipeline of 14 biosimilars, several of which have already secured approvals from leading global regulatory agencies. Its Bevacizumab biosimilar Bevqolva has received MHRA approval, while Zefylti (Filgrastim) and Dyrupeg® (Pegfilgrastim) are approved by the European Commission and MHRA. Additionally, Dazublys (Trastuzumab) has gained approvals from both the EC and 60’s CDSCO, underscoring the company’s international regulatory expertise. Beyond biosimilars, CuraTeQ operates Auro Peptides, a dedicated synthetic peptide API manufacturing unit that has filed 14 US Drug Master Files (DMFs) contributing to six successful Abbreviated New Drug Application (ANDA) approvals in the 163. This peptide expertise complements CuraTeQ’s biologics capabilities, enhancing its global value proposition. As a Contract Manufacturing Organization (CMO), CuraTeQ offers end-to-end biologics and peptide manufacturing services, helping pharmaceutical partners accelerate development, reduce costs, and meet stringent quality standards. With advanced facilities, a commitment to regulatory excellence, and a mission to improve access to affordable biologics worldwide, CuraTeQ Biologics is emerging as a global partner of choice in biosimilar development and manufacturing.